SEC Form 4 · accession 0001683168-26-004970
Valion Bio, Inc. · VBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lisa G Wolf
Officer — Chief Financial Officer
Period of report
Jun 18, 2026
Accepted (ET)
Jun 18, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001787740
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 18, 2026 | M | 92 | — | A | 618 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jun 18, 2026 | M | 92 | D | — | — | Common Stock | 92 | 551 | D |
Explanation of responses
- F1Each Restricted Stock Unit is convertible into one share of Common Stock.
- F2Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date.